(Q40294669)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

José L Cabriada

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Xavier Calvet

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

3

A Perez-Aisa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Javier Molina-Infante

5

object named as

J Molina-Infante

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1

J P Gisbert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

M Castro-Fernandez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

A Cosme

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

I Modolell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

J L Gisbert

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

E Lamas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

E Marcos

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

28 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

941-947

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22372560%20AND%20SRC:MED&resulttype=core&format=json

Clinical practice. Helicobacter pylori infection

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

In vitro activity of clarithromycin against intracellular Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Antimicrobial activity of rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Basis for the management of drug-resistant Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Efficacy of Helicobacter pylori eradication therapies: a single centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05053.X